Minims Phenylephrinhydrochlorid Bausch + Lomb Ireland Limited (Phenylephrine Hydrochloride)

Phenylephrine hydrochloride acts as a selective alpha‑1 adrenergic receptor agonist. By stimulating these receptors on conjunctival blood vessels, it causes vasoconstriction, which reduces blood flow to the ocular surface and diminishes the visible redness associated with irritation.

The appropriate dosing regimen for Minims Phenylephrinhydrochlorid is determined by the prescribing healthcare professional. Typically, one or two drops are instilled in the affected eye(s) as needed, not exceeding the frequency recommended by the prescriber.

Safety data for phenylephrine hydrochloride eye drops in pregnancy and lactation are limited. Healthcare providers should evaluate the potential benefits against any possible risks before prescribing it to pregnant or nursing individuals.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Minims contains phenylephrine hydrochloride, a selective alpha‑1 agonist, which provides rapid vasoconstriction. Compared with non‑selective decongestants, phenylephrine often offers a quicker onset of redness reduction with a lower incidence of systemic side effects when used as directed.

Store the eye‑drop bottle at room temperature, preferably below 25 °C. Keep it tightly closed, protect it from direct light and moisture, and discard any product that appears discolored or has been opened beyond the recommended period.

The product is applied topically to the eye. Before instillation, wash your hands, tilt the head back, gently pull down the lower eyelid, and place the prescribed number of drops into the conjunctival sac. Close the eye briefly and avoid blinking excessively.

Serious adverse events, although rare, include severe allergic reactions such as anaphylaxis, a marked increase in intra‑ocular pressure, and persistent eye pain or vision changes. If any of these occur, discontinue use immediately and seek medical attention.

Individuals with known hypersensitivity to phenylephrine or any formulation component should avoid the product. It is also contraindicated in patients with narrow‑angle glaucoma or those advised against vasoconstrictive agents by their eye‑care professional.